| Literature DB >> 30837304 |
Hyun-Hee Ryu1,2, TaeHyun Kim3, Jung-Woong Kim2, Minkyung Kang1,4, Pojeong Park3, Yong Gyu Kim1,4, Hyopil Kim3, Jiyeon Ha1, Ja Eun Choi3, Jisu Lee3, Chae-Seok Lim5, Chul-Hong Kim2, Sang Jeong Kim1,4,6, Alcino J Silva7, Bong-Kiun Kaang3, Yong-Seok Lee8,4,6.
Abstract
Mutations in RAS signaling pathway components cause diverse neurodevelopmental disorders, collectively called RASopathies. Previous studies have suggested that dysregulation in RAS-extracellular signal-regulated kinase (ERK) activation is restricted to distinct cell types in different RASopathies. Some cases of Noonan syndrome (NS) are associated with gain-of-function mutations in the phosphatase SHP2 (encoded by PTPN11); however, SHP2 is abundant in multiple cell types, so it is unclear which cell type(s) contribute to NS phenotypes. Here, we found that expressing the NS-associated mutant SHP2D61G in excitatory, but not inhibitory, hippocampal neurons increased ERK signaling and impaired both long-term potentiation (LTP) and spatial memory in mice, although endogenous SHP2 was expressed in both neuronal types. Transcriptomic analyses revealed that the genes encoding SHP2-interacting proteins that are critical for ERK activation, such as GAB1 and GRB2, were enriched in excitatory neurons. Accordingly, expressing a dominant-negative mutant of GAB1, which reduced its interaction with SHP2D61G, selectively in excitatory neurons, reversed SHP2D61G-mediated deficits. Moreover, ectopic expression of GAB1 and GRB2 together with SHP2D61G in inhibitory neurons resulted in ERK activation. These results demonstrate that RAS-ERK signaling networks are notably different between excitatory and inhibitory neurons, accounting for the cell type-specific pathophysiology of NS and perhaps other RASopathies.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30837304 PMCID: PMC6800025 DOI: 10.1126/scisignal.aau5755
Source DB: PubMed Journal: Sci Signal ISSN: 1945-0877 Impact factor: 8.192